ATE229017T1 - Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung - Google Patents

Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung

Info

Publication number
ATE229017T1
ATE229017T1 AT99901979T AT99901979T ATE229017T1 AT E229017 T1 ATE229017 T1 AT E229017T1 AT 99901979 T AT99901979 T AT 99901979T AT 99901979 T AT99901979 T AT 99901979T AT E229017 T1 ATE229017 T1 AT E229017T1
Authority
AT
Austria
Prior art keywords
formula
piperide
instructions
production
compound
Prior art date
Application number
AT99901979T
Other languages
English (en)
Inventor
You Seung Shin
Jong Sung Koh
Hyun Il Lee
Jin Ho Lee
Jong Hyun Kim
Hyun Ho Chung
Kwi Hwa Kim
Tae Hwan Kwak
Seong Gu Ro
In Ae Ahn
Tae Saeng Choi
Young Hoon Oh
Chung Mi Kim
Sun Hwa Lee
Hyun Sung Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019980002777A external-priority patent/KR100388789B1/ko
Priority claimed from KR1019980028340A external-priority patent/KR100388792B1/ko
Priority claimed from KR10-1998-0032150A external-priority patent/KR100388794B1/ko
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Application granted granted Critical
Publication of ATE229017T1 publication Critical patent/ATE229017T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT99901979T 1998-02-02 1999-02-01 Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung ATE229017T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR19980002776 1998-02-02
KR1019980002777A KR100388789B1 (ko) 1998-02-02 1998-02-02 피롤구조를갖는파네실전이효소억제제및그의제조방법
KR1019980028340A KR100388792B1 (ko) 1998-02-02 1998-07-14 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
KR10-1998-0032150A KR100388794B1 (ko) 1998-08-07 1998-08-07 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
PCT/KR1999/000051 WO1999038862A1 (en) 1998-02-02 1999-02-01 Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof

Publications (1)

Publication Number Publication Date
ATE229017T1 true ATE229017T1 (de) 2002-12-15

Family

ID=27483262

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99901979T ATE229017T1 (de) 1998-02-02 1999-02-01 Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung

Country Status (12)

Country Link
US (1) US6436960B1 (de)
EP (1) EP1058683B1 (de)
JP (1) JP3283032B2 (de)
CN (1) CN1158277C (de)
AT (1) ATE229017T1 (de)
AU (1) AU745855B2 (de)
BR (1) BR9908545A (de)
CA (1) CA2320233C (de)
DE (1) DE69904302T2 (de)
ES (1) ES2185307T3 (de)
PT (1) PT1058683E (de)
WO (1) WO1999038862A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100388792B1 (ko) * 1998-02-02 2003-09-22 주식회사 엘지생명과학 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
KR100388794B1 (ko) * 1998-08-07 2003-10-10 주식회사 엘지생명과학 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
JP2002543074A (ja) * 1999-04-13 2002-12-17 エルジー シーアイ リミテッド ピロール構造を有するファネシル転移酵素阻害剤及びその製造方法
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물
US7035932B1 (en) * 2000-10-27 2006-04-25 Eric Morgan Dowling Federated multiprotocol communication
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
CA2541509C (en) * 2003-10-17 2014-06-10 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1869192B1 (de) 2005-03-18 2016-01-20 MedImmune, LLC Rahmenmischung von antikörpern
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
EP3763740A1 (de) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit-antikörper und verwendungen davon
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
CN104812775B (zh) 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
JP2015533832A (ja) 2012-10-09 2015-11-26 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗Ｃ１６ｏｒｆ５４抗体およびその使用方法
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
WO2015053871A2 (en) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102226248B1 (ko) 2014-06-04 2021-03-12 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
WO2016094837A2 (en) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
EP3383908A1 (de) 2015-12-02 2018-10-10 Stsciences, Inc. Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator)
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20250036941A (ko) 2017-05-31 2025-03-14 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
EP3635007A1 (de) 2017-06-06 2020-04-15 STCube & Co., Inc. Verfahren zur behandlung von krebs unter verwendung von antikörpern und molekülen, die an btn1a1 oder btn1a1-liganden binden
CN111630069B (zh) 2017-10-13 2024-05-31 勃林格殷格翰国际有限公司 针对Thomsen-nouvelle(Tn)抗原的人抗体
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
EP0632808A1 (de) * 1992-03-25 1995-01-11 Pfizer Limited Antivirale peptide
GB9312806D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
AU715603B2 (en) * 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249601A1 (en) * 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
JP2000504023A (ja) * 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
WO1997036890A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891353A4 (de) * 1996-04-03 2001-08-08 Merck & Co Inc Farnesyl-protein transferase inhibitoren
US6268363B1 (en) * 1997-11-28 2001-07-31 Lg Chemical Ltd. Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof

Also Published As

Publication number Publication date
CN1158277C (zh) 2004-07-21
EP1058683A1 (de) 2000-12-13
DE69904302T2 (de) 2003-08-14
JP2002501918A (ja) 2002-01-22
AU745855B2 (en) 2002-04-11
CN1289331A (zh) 2001-03-28
CA2320233A1 (en) 1999-08-05
PT1058683E (pt) 2003-04-30
AU2188699A (en) 1999-08-16
ES2185307T3 (es) 2003-04-16
JP3283032B2 (ja) 2002-05-20
DE69904302D1 (de) 2003-01-16
BR9908545A (pt) 2001-10-02
CA2320233C (en) 2004-07-27
WO1999038862A1 (en) 1999-08-05
US6436960B1 (en) 2002-08-20
EP1058683B1 (de) 2002-12-04

Similar Documents

Publication Publication Date Title
DE69904302D1 (de) Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
HUP0004238A2 (hu) Farnezil-transzferáz inhibitor hatású imidazolszármazékok és eljárás előállításukra, valamint a vegyületeket tartalmazó gyógyszerkészítmények
WO2001028996A3 (en) Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases
ATE25974T1 (de) Acyl-substituierte derivate von 1,2,3,4tetrahydroisochinolin-3-carboxysaeuren, ihre salze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung.
NO950297D0 (no) Prolinamidderivater
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
NO20024772L (no) Percyquinnin, fremgangsmÕte for dets fremstilling og dets anvendelse som et legemiddel
FI810604L (fi) Foerfarande foer framstaellning av indanderivat
ATE302778T1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE60014053D1 (de) Farnesyltransferase-inhibitoren die eine pyrrolstruktur haben und verfahren zu ihrer herstellung
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
ATE61340T1 (de) Aminosaeurederivate und deren verfahren zur herstellung.
CA2406266A1 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
DK1233953T3 (da) Nye benzoethiadiazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende samme
ATE141606T1 (de) Cephemverbindungen und verfahren zu ihrer herstellung
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
NO963655L (no) Nye aminosyrederivater, fremgangsmåte for fremstilling av dem og farmasöytiske blandinger som inneholder dem
ATE214051T1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
NO20045132L (no) Benzo(c)kinolizinderivater, deres fremstilling og anvendelse som 5alfa- reduktaseinhibitorer
DK0913151T3 (da) Anti-helicobacter Pylori-præparater indeholdende 1-methylcarbapenemderivater som den aktive bestanddel
ATE307809T1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
WO2004007441A3 (fr) Derives de 4,4' -dithiobis- (3-aminobutane-1-sulfonates) nouveaux et compositions les contenant
DE69600272D1 (de) Chinolin-4-carbonylguanidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
CA2202904A1 (en) Pharmaceutical composition for prophylaxis and treatment of type i allergic diseases
EP1123923A4 (de) Dihydropyridin-derivate und drogen gemenge, die diese enthalten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties